STOCK TITAN

IGC Pharma (IGC) EPS by Year

IGC NYSE

IGC Pharma, Inc. lost $0.09 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters IGC Pharma, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$0.09
YoY n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IGC EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KTFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
EPS (Diluted)-$0.09n/m-$0.22N/AN/A-$0.21n/m-$0.19n/m-$0.13n/m-$0.06n/m-$0.07-$0.17n/m-$0.31-$0.37n/m-$0.32-$2.66-$13.40

IGC EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
EPS (Diluted)-$0.02n/m-$0.03n/m-$0.02n/mN/A-$0.02n/m-$0.02n/m-$0.02n/m-$0.02n/m-$0.02n/m-$0.03-$0.04-$0.09

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More IGC Pharma, Inc. financials

Frequently Asked Questions

IGC Pharma, Inc. lost $0.09 per diluted share in fiscal year 2025.

IGC Pharma, Inc. (IGC) reported a loss of $0.22 per diluted share in fiscal year 2024 and a loss of $0.09 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Across the 15 fiscal years this page covers, IGC Pharma, Inc. (IGC) diluted earnings per share went from -$13.40 in fiscal year 2011 to -$0.09 in fiscal year 2025.

IGC Pharma, Inc. (IGC) reported -$0.02 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what IGC Pharma, Inc. (IGC) reported on that line in every period on record.